Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.81 USD | -0.59% | -5.67% | -34.79% |
Sales 2024 * | 1.54M 2.11M | Sales 2025 * | 5.81M 7.95M | Capitalization | 712M 974M |
---|---|---|---|---|---|
Net income 2024 * | -201M -275M | Net income 2025 * | -241M -329M | EV / Sales 2024 * | 227 x |
Net cash position 2024 * | 362M 495M | Net cash position 2025 * | 377M 515M | EV / Sales 2025 * | 57.7 x |
P/E ratio 2024 * |
-3.59
x | P/E ratio 2025 * |
-3.27
x | Employees | 158 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.42% |
Latest transcript on Pliant Therapeutics, Inc.
1 day | -0.59% | ||
1 week | -5.67% | ||
Current month | -20.74% | ||
1 month | -18.83% | ||
3 months | -31.10% | ||
6 months | -11.87% | ||
Current year | -34.79% |
Managers | Title | Age | Since |
---|---|---|---|
Bernard Coulie
CEO | Chief Executive Officer | 58 | 16-01-31 |
- | - | ||
Keith Cummings
DFI | Director of Finance/CFO | 47 | 18-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 21-01-11 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 16-06-30 |
Gayle Crowell
BRD | Director/Board Member | 73 | 20-01-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.16% | 2 M€ | -.--% | ||
0.08% | 0 M€ | 0.00% | - | |
0.07% | 237 M€ | +2.89% | - | |
0.07% | 0 M€ | 0.00% | - | |
0.05% | 7 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 11.81 | -0.59% | 366,715 |
24-04-25 | 11.88 | -0.17% | 610,667 |
24-04-24 | 11.9 | -4.95% | 368,691 |
24-04-23 | 12.52 | -0.63% | 243,871 |
24-04-22 | 12.6 | +0.64% | 211,566 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.79% | 712M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- PLRX Stock